These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20367135)

  • 21. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma.
    Kayamori K; Shono K; Onoda M; Yokota A
    Hematology; 2019 Dec; 24(1):52-59. PubMed ID: 30101679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma.
    Lee GW; Go SI; Kim SH; Hong J; Kim YR; Oh S; Kim SY; Do YR; Lee H; Lee SI; Bae SH; Oh SY; Song MK; Lee WS; Lee B; Kim JS; Kim MK; Kang HJ; Ahn JS; Yhim HY; Kim HJ; Kim SJ; Kim WS; Suh C;
    Leuk Lymphoma; 2015 Apr; 56(4):1020-6. PubMed ID: 25039351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
    Porrata LF; Rsitow K; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Habermann TM; Witzig TE; Colgan JP; Nowakowski GS; Thompson CA; Markovic SN
    Leukemia; 2010 Jul; 24(7):1343-9. PubMed ID: 20485372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
    Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
    Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
    Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FcgammaRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP).
    Camilleri-Broët S; Mounier N; Delmer A; Brière J; Casasnovas O; Cassard L; Gaulard P; Christian B; Coiffier B; Sautès-Fridman C
    Leukemia; 2004 Dec; 18(12):2038-40. PubMed ID: 15470484
    [No Abstract]   [Full Text] [Related]  

  • 28. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
    Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
    Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium.
    Hainsworth JD; Flinn IW; Spigel DR; Clark BL; Griner PL; Vazquez ER; Doss HH; Shipley D; Franco LA; Burris HA; Greco FA;
    Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):44-50. PubMed ID: 20223728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.
    Derenzini E; Stefoni V; Pellegrini C; Fina MP; Broccoli A; Venturini F; Gandolfi L; Pileri SA; Martelli M; Petti MC; Perrotti A; De Renzo A; Zaja F; Baccarani M; Zinzani PL
    Leuk Lymphoma; 2009 Nov; 50(11):1824-9. PubMed ID: 19814687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy.
    Halaas JL; Moskowitz CH; Horwitz S; Portlock C; Noy A; Straus D; O'Connor OA; Yahalom J; Zelenetz AD
    Leuk Lymphoma; 2005 Apr; 46(4):541-7. PubMed ID: 16019482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.
    Nowakowski GS; LaPlant B; Habermann TM; Rivera CE; Macon WR; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Klebig RR; Reeder CB; Witzig TE
    Leukemia; 2011 Dec; 25(12):1877-81. PubMed ID: 21720383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
    Schmitz N; Zeynalova S; Nickelsen M; Kansara R; Villa D; Sehn LH; Glass B; Scott DW; Gascoyne RD; Connors JM; Ziepert M; Pfreundschuh M; Loeffler M; Savage KJ
    J Clin Oncol; 2016 Sep; 34(26):3150-6. PubMed ID: 27382100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era.
    Zaky AH; Bakry R; El-sayed MI; Elwanis MA; Nabih O
    Hematology; 2014 Oct; 19(7):412-6. PubMed ID: 24620947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
    Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A
    Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
    Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
    Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
    Choi YW; Jeong SH; Ahn MS; Lee HW; Kang SY; Choi JH; Jin UR; Park JS
    J Korean Med Sci; 2014 Nov; 29(11):1493-500. PubMed ID: 25408580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absolute lymphocyte count at day + 21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone.
    Chae YS; Shin H; Sohn SK; Lee SJ; Moon JH; Kang BW; Kim JG; Yang DH; Lee JJ; Park TI
    Leuk Lymphoma; 2012 Sep; 53(9):1757-63. PubMed ID: 22372848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
    Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
    Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
    Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
    Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.